A review of current treatment strategies for restless legs syndrome (Willis–Ekbom disease)
ABSTRACT
Restless legs syndrome (RLS), recently renamed Willis–Ekbom disease (WED), is a common movement disorder. It is characterised by the need to move mainly the legs due to uncomfortable, sometimes painful sensations in the legs, which have a diurnal variation and a release with movement. Management is complex. First, centres should establish the severity of RLS using a simple 10-item RLS severity rating scale (IRLS). They should also exclude secondary causes, in particular ensuring normal iron levels. Mild cases can be managed by lifestyle changes, but patients with a IRLS score above 15 usually require pharmacological treatment. Dopaminergic therapies remain the mainstay of medical therapies, with recent evidence suggesting opioids may be particularly effective. This article focuses on the different treatment strategies in RLS, their associated complications and ways to manage them.
Introduction
Restless legs syndrome (RLS), also known as Willis–Ekbom disease (WED), is a common neurological disorder characterised by an uncontrollable urge to move certain parts of the body, particularly the lower limbs. This is usually accompanied or caused by unpleasant sensations in the legs.1 Symptoms of RLS appear or worsen during periods of inactivity or rest and improve with activity. The estimated prevalence of RLS ranges between 5% and 15%, but figures vary widely depending upon the population surveyed and the severity of symptoms required for inclusion.2,3 RLS can be categorised as primary (idiopathic) or secondary. Secondary RLS occurs as a result of certain conditions, such as iron deficiency, pregnancy, end-stage renal disease, diabetes, rheumatoid arthritis and, occasionally, peripheral neuropathies.
Diagnosis
The diagnosis of RLS is based primarily on the patient's clinical history and on a neurological examination to exclude peripheral neuropathy. The International RLS Study Group (IRLSSG) essential diagnostic criteria for RLS were revised in 2012 and can be used in clinical practice. They include:4
an urge to move the legs usually accompanied or caused by uncomfortable sensations in the legs
worsening of symptoms during times of rest or inactivity
partial or total relief of symptoms by movement
the symptoms only occur or are worse in the evening or night
the occurrence of the above features are not solely accounted for as symptoms primary to another medical or behavioural condition (such as myalgia, venous stasis, leg oedema, arthritis, leg cramps, positional discomfort or habitual foot tapping).
More recently, a single standard question for rapid screening for RLS has been validated.5 The question, developed by the IRLSSG on the basis of standard diagnostic criteria, is: ‘When you try to relax in the evening or sleep at night, do you ever have unpleasant, restless feelings in your legs that can be relieved by walking or movement?’. As this single question had 100% sensitivity and 96.8% specificity for the diagnosis of RLS, it can be used to screen large patient groups effectively. Nevertheless, the final diagnosis should always be confirmed by matching the patient's history and symptoms with the IRLSSG diagnostic criteria, accompanied by the exclusion of secondary conditions.
Treatment
The IRLSSG rating scale (IRLS) for determining the severity of RLS consists of 10 questions, each being scored into one of five severity categories (from 0 to 4), with the maximum total score being 40.6 The severity of RLS symptoms is scored as mild (1–10), moderate (11–20), severe (21–30) and very severe (31–40). The patient's score can be used to decide whether pharmacological treatment would be beneficial.
Non-pharmacological treatment
The majority of RLS cases are mild and can be managed by lifestyle changes or non-pharmacological treatment. Lifestyle factors known to precipitate RLS symptoms are high caffeine intake7 (avoid any intake of caffeine before bedtime), excessive alcohol consumption8 (avoid any intake of alcohol before bedtime), severe stress, shift work and intense physical activity near bedtime. Furthermore, sleep hygiene is important and may help patients with RLS. It is important, therefore, for patients with RLS to consider the following as part of their bedtime routine:
a quiet, comfortable and cool sleeping environment
appropriate nightwear (such as silk pyjama or dressing gown)
regular sleep pattern (go to bed and wake up at regular hours, avoid daytime naps)
associate bed with sleep (for instance, avoid watching TV from bed).
As RLS usually affects the first part of the sleep cycle at night, patients may be advised to alter their sleep pattern by going to bed late and waking up late.
During an attack, patients may benefit from:
a hot or cold massage, rubbing or massaging the affected limbs9
bathing in hot or cold water
physical activities such as walking, stretching and exercise
relaxation exercises (eg biofeedback or yoga)
distracting the mind by mental exercises (for example, reading an interesting book during the onset of symptoms).
Many other unproven therapies have been described on the basis of individual experience, such as the use of capsaicin cream or magnesium and halcyon bracelets, but these cannot be recommended at this time.
Treating secondary causes
It is important to distinguish between primary and secondary RLS. Primary RLS tends to run a chronic course and symptoms worsen with time, especially in patients with early onset. By contrast, in secondary RLS symptoms may remit once the secondary cause (eg iron deficiency or end-stage renal disease) is treated. Iron deficiency is an important factor even in primary RLS; therefore, iron parameters (specifically serum ferritin levels) should be measured. Those with low or borderline levels require oral iron treatment for 1 to 2 months with a repeat measurement of serum ferritin levels to avoid iron overload.10 Box 1 summarises blood tests necessary to exclude secondary causes of RLS.
Patients with severe RLS and insomnia may require sleep studies such as polysomnography11 or immobilisation tests,12,13 but in practice these are rarely performed in the UK.
Avoiding medication that exacerbate restless legs syndrome
Several drugs are known to worsen RLS symptoms and, if possible, these should be avoided. Medications that are known to induce or exacerbate RLS symptoms include: antihistamines, dopamine antagonists, anti-nausea medications, anxiolytics, antidepressants (such as mirtazapine, escitalopram, fluoxetine and mianserin), neuroleptics (such as olanzapine), beta-blockers, anticonvulsants, L-thyroxine and lithium.14 In clinical practice, it is useful to enquire about medication intake and taper down the doses of any antihistamines or dopamine antagonists that are being used.
Box 1. Recommended blood tests to rule out secondary restless legs syndrome.
Pharmacological treatment
An estimated 10–15% of RLS patients have symptoms severe enough to require medical management of RLS.15 Treatment is only required when the symptoms are clinically significant. All possible treatment options only address the symptoms and are not preventive. Furthermore, as RLS is a chronic disorder, it is likely that once the patient starts medication, they will continue to use it for the rest of their lives. Therefore, RLS should be treated in order to alleviate sensory and motor symptoms, to improve sleep and quality of life and to prevent cardiovascular complications. The dosage should be kept as low as possible.
Currently, dopaminergic agents are used as first-line treatment for moderate to severe RLS. Randomised placebo controlled studies have established the efficacy of dopamine agonists (DA) in RLS for both improvement of symptoms and reduction in periodic leg movements during sleep and awakening.16 The European Federation of Neurological Societies has recommended non-ergot DAs, such as ropinirole and pramipexole as tablets or rotigotine as patches. In the UK, DAs are the only licensed treatment for RLS. The different DAs and their recommended doses are summarised in Table 1. The doses are considerably smaller than those used for patients with Parkinson's disease. DAs should be administered as a single evening dose and are effective for the short- and long-term treatment of idiopathic RLS. If the patient shows intolerance to one agent, then another DA should be tried. Oral therapies such as pramipexole and ropinirole are both effective, but their use depends on tolerability and efficacy. Rotigotine patches have the advantage of being efficacious during both the day and night, and many clinicians prescribe the patch once oral therapies have failed. DAs alleviate symptoms in up to 70% of patients.
Levodopa is used occasionally as the first-line treatment for intermittent RLS symptoms (less than three times a week) in Germany, Austria and Switzerland. It is mainly used as a rescue medication and so is taken when symptoms occur or when they are anticipated. Levodopa therapy is associated with a high rate of side effects, such as augmentation (an overall increase in RLS symptom severity) (60–80%),17 and is not recommended as first-line treatment in the UK. Levodopa can also be used as a clinical ‘challenge test’ for the diagnosis of RLS.18
Second-line off-label treatment options for daily RLS symptoms are α2δ ligands (such as gabapentin or pregabalin) and opioids (such as oxycodone, propoxyphene, tramadol, tilidine or codeine). These are particularly useful for patients with painful RLS symptoms, coexisting neuropathy or pain elsewhere.19 A recent study found that prolonged-release oxycodone-naloxone caused an 8-point reduction in the mean IRLS sum score compared to placebo. This represents one of the most effective treatment responses ever seen in RLS, and so the use of this combined medication in severe RLS is likely to be adopted.20
Table 1 summarises the different medications used for the treatment of RLS, their recommended minimum start dose, maximum dose and main important side effects.
Follow up
RLS patients should be followed up regularly to monitor treatment efficacy, as the disease tends to worsen over time. The European Restless Legs Study Group (EURLSSG) recommends that even in the absence of complications, patients need to see their physician every 6–12 months. A symptom diary completed over 7–14 days prior to the consultation could provide the physician with details about the severity of symptoms and the effect of treatment.
If a patient complains of worsening of RLS symptoms while being on treatment, the physician should check whether the patient is compliant, if they are taking any additional medication that may exacerbate symptoms or whether they have become more sedentary as this can cause symptoms to appear earlier during the day. It is important to check iron parameters during follow-up consultations as iron deficiency is implicated in the onset as well as the severity of RLS.10
Treatment complications
Early morning rebound
Early morning rebound is the reappearance of RLS symptoms in the early morning as the effects of medication are wearing off. Symptoms tend to be worse than expected if no medication was taken but they disappear several hours later. Early morning rebound occurs more frequently with short half-life medication such as levodopa.21 It is important to exclude concurrent conditions, such as depression or sleep apnoea, before modifying the current treatment. To manage this complication, the dose of the currently prescribed drug can be increased, the time of administration can be changed or another dopaminergic agent with a longer half-life can be prescribed.22
Tolerance and loss of efficacy
Tolerance consists of a decrease in the response to a drug over time, requiring an increase in dose to achieve the original amelioration of symptoms. This is to be differentiated from the natural worsening of RLS symptoms, which would also require higher drug doses. Unlike rebound or augmentation, symptoms are not worse than before treatment initiation. It is not completely known whether tolerance inevitably precedes and leads to augmentation.
Augmentation
Augmentation is a treatment-related side effect that is characterised by an overall increase in RLS symptom severity. It is the worst long-term complication of dopaminergic treatment of RLS and leads to worse symptoms than were present before treatment had been started. The Max Planck Institute (MPI) diagnostic criteria for augmentation are listed in Table 2.
Augmentation occurs more frequently in patients who take daily doses higher than the following: 200 mg levodopa, 0.5 mg pramipexole, 2 mg ropinirole or 3 mg rotigotine. The rate of augmentation is greatest with levodopa and among the DAs, it is greatest with pramipexole and lowest with rotigotine with an incidence of approximately 2–3% per year.24 Although the vast majority of augmentation cases are due to dopaminergic agents, a few cases have been reported with the use of tramadol.14,24 No other medication has been found to cause augmentation. Predictors of augmentation have been identified as low plasma ferritin levels, previous episodes of augmentation, longer treatment duration and possibly a preceding tolerance to medication.24,25
Several approaches can be taken to prevent augmentation. The most effective preventative measure is to prescribe the lowest effective dose of dopaminergic medication. Ideally, a low dose of a long-acting dopaminergic agent (such as rotigotine) should be used; conversely, agents with high rates of augmentation (such as levodopa) should be avoided. Another measure is to divide the dopaminergic dose, administering the first dose earlier in the afternoon before symptom onset and the second dose after symptoms started. Divided dose of RLS medication has not, however, been approved yet. As low iron body stores may be responsible for the augmentation, iron parameters should be measured and an oral iron intake must be considered if serum ferritin is below 50 μg/l.
When the measures described above are unsuccessful and symptoms are so severe that they interfere with the patient's daily activities, a different DA may be prescribed. Augmentation is, however, likely to reoccur even when another dopaminergic agent is used. If changing dopaminergic agents does not improve symptoms, the dopaminergic dose should be further reduced while simultaneously initiating treatment with a non-dopaminergic agent (such as an α2δ ligand or an opiate), until the dopaminergic agent is discontinued altogether.26
Impulse control disorders
Impulse control disorders (ICD) are a well-known side effect of dopaminergic agents in patients with Parkinson's disease.27 They have also recently been described in RLS, despite the lower doses of dopaminergic medication used by these patients. ICDs during RLS treatment are estimated to affect between 3% and 17% of patients and include obsessive-compulsive behaviour, hypersexuality, binge eating, pathologic gambling, punding and compulsive shopping.28–30 The incidence of ICDs is dose-dependent and ceases when dopaminergic treatment is stopped. If ICDs occur during treatment with a dopaminergic agent, the medication should be either discontinued or progressively decreased until the side effect resolves, or until another non-dopaminergic drug can be substituted or added.
Weight gain
Sleep loss has been shown to be related to weight gain and obesity.31 Between 20% and 30% of patients with RLS eat during the night. It is important to differentiate weight gain, fluid retention (oedema) and binge eating. Weight gain is also a common side effect of α2δ ligands and appears to be dose-dependent. Water retention can also occur with dopaminergic agents.
Mood changes
Depression and anxiety are common comorbid conditions associated with RLS.32 Patients with RLS, especially those who are taking α2δ ligands, are at greater risk of developing depression than healthy individuals. Furthermore, augmentation is a common trigger of anxiety. If depression occurs, the physician should avoid prescribing an antidepressant that is known to worsen RLS symptoms, such as a selective norepinephrine reuptake inhibitor (SNRI) or a selective serotonin reuptake inhibitor (SSRI). Suitable antidepressants include duloxetine, buproprion, lamictal, trazadone and desipramine. Cognitive behaviour therapy can also be of benefit.
Conclusions
RLS is a common condition and can have a great impact on quality of life, mainly because of disturbed night time sleep and daytime sleepiness. Treatment depends on the severity and frequency of symptoms, which can be determined by using the IRLSSG rating scale. Mild RLS may be managed with reassurance and lifestyle changes. Moderate to severe cases require pharmacological treatment. Secondary causes and exacerbating factors should be identified and treated. Patients with poorly managed RLS can suffer from severe morbidity and a poor quality of life associated with marked anxiety and, sometimes, depression.
Conflict of interest
Lisa Klingelhoefer, Ilaria Cova and Sheena Gupta declare that there are no competing interests concerning this article. Kallol Ray Chaudhuri is a founding member of RLS UK and declares that there are no competing interests concerning this article.
- © 2014 Royal College of Physicians
References
- ↵
- Allen RP,
- Picchietti D,
- Hening WA,
- et al.
- ↵
- ↵
- ↵
- International Restless Legs Syndrome Study Group
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- Garcia-Borreguero D,
- Kohnen R,
- Silber MH,
- et al.
- ↵
- ↵
- ↵
- ↵
- Trenkwalder C,
- Benes H,
- Grote L,
- et al.
- ↵
- ↵
- ↵
- Garcia-Borreguero D,
- Allen RP,
- Kohnen R
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
Article Tools
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.